Objective  To conduct a statistical analysis of the clinical application of warfarin sodium tablets prepared with three-dimensional (3D) printing technology in different dosages, aiming to evaluate the feasibility and effectiveness of 3D-printed warfarin sodium tablets in clinical practice.

Methods  According to the commonly used clinical doses, warfarin sodium and excipients were prepared into tablets in set proportions using 3D printing technology. Retrospective statistics on the application of 3D printed warfarin sodium tablets in each department Guangdong Provincial People’s Hospital Southern Medical University and the distribution of the use of different dosages during the period from January 2023 to December 2023 were obtained through the hospital information system and the China Hospital Pharmacovigilance System. The international normalized ratio (INR) compliance rate and the number of dose adjustments were assessed in patients taking 3D printed warfarin sodium tablets (3D printing group) and patients not taking 3D printed warfarin sodium tablets (non-3D printing group), and the satisfaction of patients, pharmacists, and healthcare professionals with 3D printed warfarin sodium tablets was investigated.

Results  The main application departments of 3D printed warfarin sodium tablets were cardiac surgery, followed by cardiology and obstetrics. The most widely used dose distribution was 2.25 mg, followed by 0.75 mg. In the hospital-wide application, the INR compliance rate was significantly higher in the 3D printing group than that in the non-3D printing group (P<0.05). the number of dose adjustments in the 3D printing group was significantly less than that in the non-3D printing group (P<0.05). The satisfaction survey showed that most of the patients, pharmacists and healthcare professionals were willing to continue using 3D printed warfarin sodium tablets as a dosage form.

Conclusion  3D printing technology for the preparation of warfarin sodium tablets has more stable INR control and less need for dose adjustment, which can better meet patients' individualized medication needs, reduce dosage errors, and be recognized by clinical medical workers and patients..

1.Pirmohamed M. Warfarin: almost 60 years old and still causing problems[J]. Br J Clin Pharmacol, 2006, 62(5): 509-511. DOI: 10.1111/j.1365-2125.2006.02806.x.

2.Shaw K, Amstutz U, Kim RB, et al. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy[J]. Ther Drug Monit, 2015, 37(4): 428-436. DOI: 10.1097/FTD.0000000000000192.

3.宋子扬, 关玮伟, 梅冬, 等. 30家医疗机构儿科用药临时调配现状的调查与思考[J]. 实用药物与临床 2022, 25(8): 764-768. [Song ZY, Guan WW, Mei D, et al. Investigation and reflection on the current situation of extemporaneous compoun ding of drugs for children in 30 medical institutions[J]. Practical Pharmacy and Clinical Remedies, 2022, 25(8): 764-768.] DOI: 10.14053/j.cnki.ppcr.202208019.

4.Peng H, Han B, Tong T, et al. 3D printing processes in precise drug delivery for personalized medicine[J]. Biofabrication, 2024, 16(3): 10.1088/1758-5090/ad3a14. DOI: 10.1088/1758-5090/ad3a14.

5.林威, 皮雪莹, 吕洁琼, 等. 3D打印技术用于市售华法林钠片与氢氯噻嗪片的精确分剂量[J]. 药学学报, 2018, 53(11): 1901-1907. [Lin W, Pi XY, Lyu JQ, et al. Precise dosage of commercial warfarin sodium tablets and hydrochlorothiazide tablets by 3D printing[J]. Acta Pharmaceutica Sinica, 2018, 53(11): 1901-1907.] DOI: 10.16438/j.0513-4870.2018-0548.

6.田盼, 陈燕忠, 杨帆, 等. 3D打印华法林钠片的质量评价[J]. 中国医院药学杂志, 2019, 39(3): 239-243. [Tian P, Chen YZ, Yang F, et al. Quality assessment of warfarin sodium tablets produced by 3D printing[J]. Chinese Journal of Hospital Pharmacy, 2019, 39(3): 239-243.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.03.05.

7.中华医学会心血管分会, 中国生物医学工程学会分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. DOI: 10.3760/cma.j.cn112148-20230416-00221.

8.中国医学会心血管病学分会, 华法林抗凝治疗的中国专家共识[J]. 中华内科杂志, 2013, 52(1): 76-82. DOI: 10.3760/cma.j.issn.0578-1426.2013.01.027.

9.Cheng TO. Chinese patients require lower dosage of warfarin[J]. Int J Cardiol, 2010, 139(1): 1. DOI: 10.1016/j.ijcard.2009.06.056.

10.Zhou XM, Zhuang W, Hu JG, et al. Low-dose anticoagulation in Chinese patients with mechanical heart valves[J]. Asian Cardiovasc Thorac Ann, 2005, 13(4): 341-344. DOI: 10.1177/021849230501300410.

11.许建屏, 石应康, 董力, 等. 中国人心脏瓣膜置换术后低强度抗凝治疗3000例随访1年报告[J]. 四川大学学报（医学版）, 2016, 47(1): 90-92. [Xu JP, Shi YK, Dong L, et al. Low intensity anticoagulation therapy for Chinese population with heart valve replacement-3000 cases follow-up[J]. Journal of Sichuan University (Medical Sciences), 2016, 47(1): 90-92.] DOI: 10.13464/j.scuxbyxb.2016.01.020.

12.Zhou XM, Zhuang W, Hu JG, et al. Low-dose anticoagulation in Chinese patients with mechanical heart valves[J]. Asian Cardiovasc Thorac Ann, 2005, 13(4): 341-344. DOI: 10.1177/ 021849230501300410.

13.翁夕洋. 低强度华法林抗凝对老年非瓣膜性房颤患者肾功能、血栓栓塞及出血发生率的影响[J]. 中外医学研究, 2022, 20(26): 127-130. [Weng XY. Effects of low-intensity warfarin anticoagulation on renal function, incidence of thromboembolism and bleeding in elderly patients with non valvular atrial fibrillation[J]. Chinese and Foreign Medical Research, 2022, 20(26): 127-130.] DOI: 10.14033/j.cnki.cfmr.2022.26.034.

14.聂亚茹, 吴建华, 李贝贝,等. 低剂量华法林对心房颤动患者脑卒中和凝血指标的影响[J]. 药物评价研究, 2020, 43(9): 1844-1847. [Nie YR, Wu JH, Li BB, et al. Effect sof low dose warfarin on stroke and coagulation indexes in patients with atrial fibrillation[J]. Drug Evaluation Research, 2020, 43(9): 1844-1847.] DOI: 10.7501/j.issn.1674-6376.2020.09.031.

15.中华医学会老年医学分会心血管学组,中国老年保健医学研究会老年心血管病分会. 老年心房颤动诊治中国专家共识（2024）[J]. 中华心律失常学杂志, 2024, 28(2): 103-124. DOI: 10.3760/cma.j.cn113859-20240130-00012.

16.中华医学会胸心血管外科分会瓣膜病外科学组. 心脏瓣膜外科抗凝治疗中国专家共识[J]. 中华胸心血管外科杂志, 2022, 38(3): 164-174. DOI: 10.3760/cma.j.cn112434-20220126-00028.

17.代佳, 姜志斌, 龚伟, 等. 华法林在心脏瓣膜置换术后抗凝强度的临床分析[J]. 继续医学教育, 2017, 31(5): 145-147. [Dai  J, Jiang ZB, Hong W, et al. Clinical analysis of anticoagulation intensity of warfarin after heart valve replacement surgery[J]. Continuing Medical Education, 2017, 31(5): 145-147.] DOI: 10.3969/j.issn.1004-6763.2017.05.079.

18.贾晓英, 韩艳艳, 王晓锋. 心脏机械瓣膜置换术后华法林抗凝治疗效果及INR抗凝强度范围分析[J]. 现代诊断与治疗, 2020, 31(12): 1918-1920. [Jia XY, Han YY, Wang XF, et al. Analysis of the efficacy of warfarin anticoagulation and INR intensity range after mechanical heart valve replacement[J]. Modern Diagnosis & Treatment, 2020, 31(12): 1918-1920.] DOI: 1011-8174（2020）12-1918-02.

19.武云涛, 高迎春, 田国祥, 等. 不同强度华法林抗凝治疗非瓣膜病性房颤患者疗效长期随访研究[J]. 心血管康复医学杂志, 2016, 25(2): 153-157. [Wu YT, Gao YC, Tian GX, et al. Long-term follow-up study of warfarin anticoagulant therapy effect of different intensity on patients with nonvalvular atrial fibrillation[J]. Chinese Journal of Cardiovascular Rehabilitation Medicine, 2016, 25(2): 153-157.] DOI: 10.3969/j.issn.1008-0074.2016.02.12.

20.陈健佳. 不同强度华法林预防非瓣膜性房颤患者栓塞性疾病的效果观察[J]. 中国实用医药, 2020, 15(3): 95-96. [Chen  JJ. Observation of effect of different intensity of warfarin in prevention of embolic diseases in patients with non-valvular atrial fibrillation[J]. China Practical Medical, 2020, 15(3): 95-96.] DOI: 10.14163/j.cnki.11-5547/r.2020.03.045.

21.Ginsberg JS, Hirsh J. Optimum use of anticoagulants in pregnancy[J]. Drugs, 1988, 36(4): 505-512. DOI: 10.2165/00003495-198836040-00007

22.Czuprynska J, Patel JP, Arya R. Current challenges and future prospects in oral anticoagulant therapy[J]. Br J Haematol, 2017, 178(6): 838-851. DOI: 10.1111/bjh.14714.

23.荣春蕾, 刘青芝, 张博, 等. 某院2020年华法林临床用药合理性分析研究[J]. 中国合理用药探索, 2024, 21(4): 89-93. [Rong Cl, Liu QZ, Zhang B, et al. Analysis on the rationality of clinical use of warfarin in a hospital in 2020[J]. China Licensed Pharmacist, 2024, 21(4): 89-93.] DOI: 10.3969/j.issn.2096-3327.2024.04.013.

24.向云霞, 蒲文, 李明清, 等. MTM模式下心脏瓣膜置换术后患者服用华法林的抗凝治疗效果评价[J]. 新疆医学, 2023, 53(11): 1304-1307, 1343. [Xiang YX, Pu W, Li MQ ,et al Evaluation of anticoagulant treatment effect of warfarin in patients after heart valve replacement in MTM mode[J]. Xinjiang Medical Journal , 2023, 53(11): 1304-1307, 1343.] https://www.cnki.com.cn/Article/CJFDTOTAL-XJYI202311002.htm.

25.Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial[J]. Lancet, 2010, 376(9745): 975-983. DOI: 10.1016/S0140-6736(10)61194-4.

26.Shah J, Snider B, Clarke T, et al. Large-scale 3D printers for additive manufacturing: design considerations and challenges[J]. International Journal of Advanced Manufacturing Technology, 2019, 104(2): 1-15. DOI: 10.1111/bjh.14714.

27.Coburn JC, Grant GT. FDA Regulatory pathways and technical considerations for the 3d printing of medical models and devices[J/OL]. (2017-07-07)[2024-11-11]. https://link.springer.com/chapter/10.1007/978-3-319-61924-8_10#citeas.